BioArctic announces Novartis' decision to terminate their collaboration agreement, affecting ongoing research efforts in neurodegenerative diseases.

BioArctic has announced that Novartis Pharma AG has decided to terminate their collaboration agreement signed in August 2025, affecting a planned treatment exploring innovative technology.

BioArctic (BIOA B) received notice that Novartis Pharma has decided to terminate their agreement exploring a potential combination treatment. The Option, Collaboration and License Agreement, entered into in August 2025, paired BioArctic's BrainTransporter technology with an undisclosed Novartis antibody. BioArctic said the termination follows Novartis's decision to discontinue the program and is unrelated to BrainTransporter.BioArctic will retain the full USD 30 million upfront payment and recognize its remaining unrecognized portion as revenue in 2026. The company has entered into five collaboration agreements using BrainTransporter to date.

Stockholm: BioArctic AB (publ) has announced that the company has entered into an option, collaboration and license agreement with Novartis Pharma AG regarding a potential new treatment combining...

Reported Monday, Jun 22 - 5:24am EDT (TheFly subscription required to read more.)

Reported Tuesday, Aug 26 - 5:19am EDT (TheFly subscription required to read more.)

Investing.com -- BioArctic AB (ST:BIOAb) shares jumped more than 13% on Tuesday after the company said it signed an option, collaboration and license agreement with Novartis to apply its BrainTransporter technology to a neurodegeneration target that has not been disclosed. The Stockholm-based company said it will receive an upfront payment of $30 million under the deal. If Novartis chooses to exercise its option to license a drug candidate from the collaboration, BioArctic could receive up to $772 million in milestone payments. The agreement also includes tiered mid-single-digit royalties on any future global product sales. Novartis will hold full responsibility for worldwide development and commercialization of the drug candidate . The agreement is the third involving BioArctic’s BrainTransporter platform. Earlier deals included a research evaluation agreement with Eisai for BAN2802 and a global license agreement with Bristol Myers Squibb for BioArctic’s PyroGlutamate-amyloid-beta antibody program, where BAN2803 uses the technology. BioArctic said it continues to retain rights to the platform for additional collaborations. 3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads. The fastest way to find out is with our Fair Value calculator. We use a mix of 17 proven industry valuation models for maximum accuracy. Get the bottom line for NOVN plus thousands of other stocks and find your next hidden gem with massive upside. Full access now available at 50% off while our Summer Sale lasts. Hurry, offer ends soon!

BioArctic collaborates with Eli Lilly, combining their BrainTransporter technology with a Lilly drug candidate to enhance treatments for neurodegeneration, ensuring better drug delivery to the brain.

The partnership between BioArctic and Eli Lilly marks a significant step in developing treatments for neurodegenerative diseases by combining unique technologies.

BioArctic AB has forged a partnership with Novartis, centered on the innovative BrainTransporter™ technology, including an upfront payment of $30 million.

BioArctic and Novartis finalize a significant collaboration utilizing BrainTransporter™. The $30 million agreement could expand to $772 million.

BioArctic and Bristol Myers Squibb have announced an exclusive licensing agreement for the PyroGlu-Aβ antibody program, promising significant potential in Alzheimer's therapy.

BioArctic can receive up to $770M more plus tiered royalties as Lilly takes over global development and commercialization of the drug candidate.

STOCKHOLM, June 22, 2026 /PRNewswire/ -- BioArctic AB (publ) (NASDAQ STOCKHOLM: BIOA B) today announced that the company has entered into a research and collaboration agreement with Eli Lilly and Company regarding a potential new treatment combining BioArctic's proprietary...

STOCKHOLM, June 22, 2026 /PRNewswire/ -- BioArctic AB (publ) (NASDAQ STOCKHOLM: BIOA B) today announced that the company has entered into a research and collaboration agreement with Eli Lilly and Company regarding a potential new treatment combining BioArctic's proprietary...

STOCKHOLM, Aug. 26, 2025 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that the company has entered into an option, collaboration and license agreement with Novartis Pharma AG regarding a potential new treatment combining BioArctic's proprietary...

STOCKHOLM, Aug. 26, 2025 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that the company has entered into an option, collaboration and license agreement with Novartis Pharma AG regarding a potential new treatment combining BioArctic's proprietary...

STOCKHOLM, Aug. 26, 2025 /PRNewswire/ — BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that the company has entered into an option, collaboration and license agreement with Novartis Pharma AG regarding a potential new treatment combining BioArctic’s proprietary BrainTransporter technology with an undisclosed target in neurodegeneration. As part of the initial research collaboration, BioArctic …